Best strategies for global HCV eradication

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 68-79

  Hagan, Liesl M ^a   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cure; Direct acting antiviral; Linkage to care; Prevention; Testing; Universal screening

Indexed keywords

ABT 072; ABT 267; ABT 333; ABT 450; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BMS 791325; DACLATASVIR; DANOPREVIR; HEPATITIS C VACCINE; INTERLEUKIN 28B; MERICITABINE; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL THERAPY; BLOOD DONOR; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEPRESSION; DNA POLYMORPHISM; DRUG ABUSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENOTYPE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; INSTRUMENT STERILIZATION; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MIXED INFECTION; MORTALITY; POSTTRANSFUSION HEPATITIS; PREGNANT WOMAN; PREVALENCE; PRISON; PRISONER; QUALITY ADJUSTED LIFE YEAR; REINFECTION; REVIEW; RISK FACTOR; SCREENING; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SYRINGE; TREATMENT OUTCOME; VACCINATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PREDICTIVE VALUE OF TESTS; PUBLIC OPINION; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; VIRAL HEPATITIS VACCINES; VULNERABLE POPULATIONS; WORLD HEALTH;

EID: 84872020388     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12063     Document Type: Review

References (123)

1. World Health Organization. Smallpox fact sheet. 2001 Available at http://www.who.int/mediacentre/factsheets/smallpox/en/ Accessed: 24 September 2012.
2. World Health Organization. Poliomyelitis fact sheet. February 2012 Available at http://www.who.int/mediacentre/factsheets/fs114/en/ Accessed: 24 September 2012.
3. World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.
4. Sherlock DS. Chronic hepatitis C. Dis Mon 1994; 40: 117-96.
5. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
6. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-91.
7. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 560-7.
8. Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 146-50.
9. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.
10. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18(Suppl. 1): 1-16.
11. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
12. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl. 1): S10-5.
13. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006; 44: 455-61.
14. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.
15. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
16. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-7.
17. United States Department of Health & Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care & treatment of viral hepatitis. Washington, DC 2011.
18. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.
19. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
20. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 7-16.
21. World Health Organization. Blood safety and availability: facts and figures from the 2007 Blood Survey. 2012 Available at http://www.drmahwish.com/publications/blood-safety-and-availability-who/ Accessed: 25 September 2012.
22. Madwar MA, El-Gindy I, Fahmy HM, Shoeb NM, Massoud BA. Hepatitis C virus transmission in family members of Egyptian patients with HCV related chronic liver disease. J Egypt Public Health Assoc 1999; 74: 313-32.
23. de Waure C, Cefalo C, Chiaradia G, et al. Intrafamilial transmission of hepatitis C virus in Italy: a systematic review. J Epidemiol Community Health 2010; 64: 843-8.
24. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 1998; 74: 399-404.
25. Stroffolini T, Lorenzoni U, Menniti-Ippolito F, Infantolino D, Chiaramonte M. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96: 3138-41.
26. Marincovich B, Castilla J, del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79: 160-2.
27. Caporaso N, Ascione A, Stroffolini T. Spread of hepatitis C virus infection within families. Investigators of an Italian Multicenter Group. J Viral Hepat 1998; 5: 67-72.
28. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: khuzestan. World J Gastroenterol 2006; 12: 7025-8.
29. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S99-105.
30. Ghosn J, Leruez-Ville M, Chaix ML. Sexual transmission of hepatitis C virus. Presse Med 2005; 34: 1034-8.
31. Russell M, Chen MJ, Nochajski TH, et al. Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health 2009; 99(Suppl. 1): S173-9.
32. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-91.
33. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60: 945-50.
34. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany-a case-control study. PLoS ONE 2011; 6: e17781.
35. Centers for Disease Control and Prevention, Division of Viral Hepatitis. Hepatitis C FAQs for health professionals. 2012 Available at http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed: 22 July 2012.
36. Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838-55.
37. Centers for Disease Control and Prevention. Progress toward prevention and control of hepatitis C virus infection-Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 2012; 61: 545-9.
38. Lawitz E, Poordad F, Kowdley K, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive IL28B-CC genotype infected subject. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
39. Poordad F, Lawitz E, Kowdley K, et al. 12-week interferon-free regimen of ABT-450/R+ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
40. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleoside NS5B inhibitor), ± ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
41. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.
42. Alter HJ, Liang TJ, Hepatitis C. The end of the beginning and possibly the beginning of the end. Ann Intern Med 2012; 156: 317-8.
43. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
44. Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15: 383-6.
45. Nguyen NH, VuTien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17: 691-7.
46. Zhou YQ, Wang XH, Hong GH, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011; 18: 595-600.
47. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-62.
48. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
49. National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C. NIH Consensus State-of-the-Science Statements 2002; 19: 1-46.
50. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
51. Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS ONE 2012; 7: e41209.
52. Hsu CS, Kao JH. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2012; 6: 497-506.
53. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18 e5.
54. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
55. Delwaide J, El Saouda R, Gerard C, Belaiche J. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17: 1185-9.
56. Doucette KE, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol 2009; 23: 421-4.
57. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-8.
58. Niederau C, Huppe D, Zehnter E, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012; 18: 1339-47.
59. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
60. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 151-6.
61. Putka B, Mullen K, Birdi S, Merheb M. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat 2009; 16: 814-21.
62. Irving WL, Smith S, Cater R, et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006; 13: 264-71.
63. Wagner G, Ryan G, Osilla KC, et al. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS 2009; 23: 715-25.
64. Gane E, Stedman C, Hyland R, et al. ELECTRON: Once daily PSI-7977 plus RBV in HCV GT1/2/3. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver. Barcelona, Spain, 2012.
65. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. In: The International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 2012.
66. Thomas DL. Advances in the treatment of hepatitis C virus infection. Top Antivir Med 2012; 20: 5-10.
67. Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17: 77-90.
68. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-90.
69. Hagan LM, Yang Z, Schinazi RF. Cost-effectiveness of all-oral, interferon-free treatment for chronic hepatitis C. In: Bridging the Sciences S2E-HCV Workshop: Seek, Test, Treat, Eradicate HCV. Atlanta, GA, 2012.
70. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 2012; 22: 391-415.
71. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408-14.
72. Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res 2012; 96: 36-50.
73. Lambotin M, Barth H, Moog C, et al. Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines 2012; 11: 791-804.
74. World Health Organization. Initiative for vaccine research, viral cancers, hepatitis C virus. 2010 Available at http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html. Accessed: 27 September 2012.
75. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
76. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
77. Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect Dis 2011; 11: 160.
78. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
79. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70.
80. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001; 111: 614-21.
81. Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 435-43.
82. Morano J, Gibson B, Altice F. Correlates of HIV, HCV, and HIV/HCV co-infection in a Northeastern inner city population. In: The Liver Meeting, 63rd Annual Meeting of the America Association for the Study of Liver Diseases. Boston, MA, 2012.
83. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006; 6: 170.
84. Weissing L, Roy K, Sapinho D, et al. Surveillance of Hepatitis C Infection Among Injecting Drug Users in the European Union. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2006.
85. Centers for Disease Control and Prevention. IDU HIV Prevention: Hepatitis C virus and HIV coinfection. 2002 Available at http://www.cdc.gov/idu/hepatitis/hepc_and_hiv_co.pdf. Accessed: 26 September 2012.
86. Schlicting EG, Johnson ME, Brems C, et al. Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci 2003; 16: 99-106.
87. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 537-41.
88. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-43.
89. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-5.
90. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005; 40(Suppl. 5): S339-45.
91. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl. 5): S325-9.
92. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
93. Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.
94. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605-11.
95. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271: 115-20.
96. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Part 1): 809-16.
97. Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA 2012; 307: 1259-60.
98. Macalino GE, Dhawan D, Rich JD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005; 95: 1739-40.
99. Federal Bureau of Prisons. Clinical practice guidelines, evaluation and treatment of hepatitis C and cirrhosis. May 2012.
100. Federal Bureau of Prisons. Clinical practice guidelines, management of HIV. June 2011.
101. Centers for Disease Control and Prevention. Viral hepatitis populations: HIV/AIDS and viral hepatitis. 2012 Available at http://www.cdc.gov/hepatitis/Populations/hiv.htm Accessed: 26 September 12012.
102. Pramoolsinsap C, Sirikulchayanonta V, Busakorn W, et al. Coinfections with hepatitis g and/or c virus in hepatitis B-related chronic liver disease. Southeast Asian J Trop Med Public Health 1999; 30: 741-9.
103. Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994; 21: 159-66.
104. Brown J, Dourakis S, Karayiannis P, et al. Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology 1992; 15: 175-9.
105. Riezu-Boj JI, Parker D, Civeira MP, et al. Detection of hepatitis C virus antibodies with new recombinant antigens: assessment in chronic liver diseases. J Hepatol 1992; 15: 309-13.
106. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
107. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254-8.
108. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
109. Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 102-7.
110. Shebl FM, El-Kamary SS, Saleh DA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009; 81: 1024-31.
111. Valladares G, Chacaltana A, Sjogren MH. The management of HCV-infected pregnant women. Ann Hepatol 2010; 9(Suppl.): 92-7.
112. Sheikh SM. Hepatitis B and C: value of universal antenatal screening. J Coll Physicians Surg Pak 2009; 19: 179-82.
113. Kuhn L, Aldrovandi GM, Sinkala M, et al. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child HIV transmission. AIDS 2010; 24: 1374-7.
114. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-81.
115. Fitzgerald FC, Bekker LG, Kaplan R, et al. Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. S Afr Med J 2010; 100: 827-31.
116. Madurga Revilla P, Aguar Carrascosa M, Pereda Perez A, et al. Retrospective study of risk factors of vertical transmission of hepatitis C virus. An Pediatr (Barc) 2012; 76: 336-42.
117. Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without Ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
118. Kowdley K, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
119. Everson G, Sims K, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of Daclatasvir, Asunaprevir, and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype 1 chronic HCV infection. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
120. Gane E, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver, Barcelona, Spain, 2012.
121. Field J, Jacobson I, Jensen D, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir, mericitabine, and ribavirin plus or minus peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
122. Pawlotsky J, Sarin S, Foster G, et al. Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. In: The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
123. Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of B1201335 and B1207127, ± ribavirin, in treatment-naive patients with chronic genotype 1 HCV infection: Interim results of SOUND-C2. In: The International Liver Congress, 47th Annual Meeting of the European Society for the Study of the Liver, Barcelona, Spain, 2012.